Information Provided By:
Fly News Breaks for October 23, 2015
CEMP
Oct 23, 2015 | 08:50 EDT
SunTruist continues to expect the U.S. and EU to approve Cempra's solithromycin for CABP after speaking with experts about the matter. However, the firm warns that side effects seen in a study of the drug could limit its uptake, and SunTrust cut its price target on the name to $43 from $58. However, the firm thinks the drop in the stock price following the data was overdone, and it keeps a Buy rating on the shares.
News For CEMP From the Last 2 Days
There are no results for your query CEMP